Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | USP8 | P40818 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25991975 | 0.88 | ADORA1 (0.35) | TRPV4DHODHADORA1ADORA2AADORA2B | |
| SCHEMBL25992003 | 0.79 | KHK (0.36) | TRPV4DHODHADORA1ADORA2AADORA2B | |
| SCHEMBL25991969 | 0.78 | TRPV4 (0.38) | TRPV4ADORA1ADORA2AADORA2BKHK | |
| SCHEMBL25991973 | 0.77 | TRPV4 (0.36) | TRPV4ADORA1ADORA2AADORA2BKHK | |
| SCHEMBL25991997 | 0.77 | TRPV4 (0.33) | TRPV4ADORA1ADORA2AADORA2BKHK | |
| SCHEMBL25991962 | 0.75 | KHK (0.40) | TRPV4DHODHADORA1ADORA2AADORA2B | |
| SCHEMBL25992002 | 0.74 | KHK (0.36) | TRPV4KHK | |
| SCHEMBL25992018 | 0.73 | ADORA1 (0.43) | ADORA1ADORA2AADORA2B | |
| SCHEMBL185766 | 0.71 | TRPV4 (0.64) | TRPV4DHODHADORA1ADORA2AADORA2B | |
| SCHEMBL25991971 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263053-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230263053-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263053-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | PPOX, CRY1, CRY2 | TRPV4 473/4885DHODH 161/4885ADORA1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.